Cargando…
A γ-Glutamyl Transpeptidase (GGT)-Triggered Charge Reversal Drug-Delivery System for Cervical Cancer Treatment: In Vitro and In Vivo Investigation
Neutral/negatively charged nanoparticles are beneficial to reduce plasma protein adsorption and prolong their blood circulation time, while positively charged nanoparticles easily transverse the blood vessel endothelium into a tumor and easily penetrate the depth of the tumor via transcytosis. Γ-Glu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221838/ https://www.ncbi.nlm.nih.gov/pubmed/37242579 http://dx.doi.org/10.3390/pharmaceutics15051335 |
_version_ | 1785049552199352320 |
---|---|
author | Fu, Jingxin Lu, Likang Li, Manzhen Guo, Yaoyao Han, Meihua Guo, Yifei Wang, Xiangtao |
author_facet | Fu, Jingxin Lu, Likang Li, Manzhen Guo, Yaoyao Han, Meihua Guo, Yifei Wang, Xiangtao |
author_sort | Fu, Jingxin |
collection | PubMed |
description | Neutral/negatively charged nanoparticles are beneficial to reduce plasma protein adsorption and prolong their blood circulation time, while positively charged nanoparticles easily transverse the blood vessel endothelium into a tumor and easily penetrate the depth of the tumor via transcytosis. Γ-Glutamyl transpeptidase (GGT) is overexpressed on the external surface of endothelial cells of tumor blood vessels and metabolically active tumor cells. Nanocarriers modified by molecules containing γ-glutamyl moieties (such as glutathione, G-SH) can maintain a neutral/negative charge in the blood, as well as can be easily hydrolyzed by the GGT enzymes to expose the cationic surface at the tumor site, thus achieving good tumor accumulation via charge reversal. In this study, DSPE-PEG2000-GSH (DPG) was synthesized and used as a stabilizer to generate paclitaxel (PTX) nanosuspensions for the treatment of Hela cervical cancer (GGT-positive). The obtained drug-delivery system (PTX-DPG nanoparticles) was 164.6 ± 3.1 nm in diameter with a zeta potential of −9.85 ± 1.03 mV and a high drug-loaded content of 41.45 ± 0.7%. PTX-DPG NPs maintained their negative surface charge in a low concentration of GGT enzyme (0.05 U/mL), whereas they showed a significant charge-reversal property in the high-concentration solution of GGT enzyme (10 U/mL). After intravenous administration, PTX-DPG NPs mainly accumulated more in the tumor than in the liver, achieved good tumor-targetability, and significantly improved anti-tumor efficacy (68.48% vs. 24.07%, tumor inhibition rate, p < 0.05 in contrast to free PTX). This kind of GGT-triggered charge-reversal nanoparticle is promising to be a novel anti-tumor agent for the effective treatment of such GGT-positive cancers as cervical cancer. |
format | Online Article Text |
id | pubmed-10221838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102218382023-05-28 A γ-Glutamyl Transpeptidase (GGT)-Triggered Charge Reversal Drug-Delivery System for Cervical Cancer Treatment: In Vitro and In Vivo Investigation Fu, Jingxin Lu, Likang Li, Manzhen Guo, Yaoyao Han, Meihua Guo, Yifei Wang, Xiangtao Pharmaceutics Article Neutral/negatively charged nanoparticles are beneficial to reduce plasma protein adsorption and prolong their blood circulation time, while positively charged nanoparticles easily transverse the blood vessel endothelium into a tumor and easily penetrate the depth of the tumor via transcytosis. Γ-Glutamyl transpeptidase (GGT) is overexpressed on the external surface of endothelial cells of tumor blood vessels and metabolically active tumor cells. Nanocarriers modified by molecules containing γ-glutamyl moieties (such as glutathione, G-SH) can maintain a neutral/negative charge in the blood, as well as can be easily hydrolyzed by the GGT enzymes to expose the cationic surface at the tumor site, thus achieving good tumor accumulation via charge reversal. In this study, DSPE-PEG2000-GSH (DPG) was synthesized and used as a stabilizer to generate paclitaxel (PTX) nanosuspensions for the treatment of Hela cervical cancer (GGT-positive). The obtained drug-delivery system (PTX-DPG nanoparticles) was 164.6 ± 3.1 nm in diameter with a zeta potential of −9.85 ± 1.03 mV and a high drug-loaded content of 41.45 ± 0.7%. PTX-DPG NPs maintained their negative surface charge in a low concentration of GGT enzyme (0.05 U/mL), whereas they showed a significant charge-reversal property in the high-concentration solution of GGT enzyme (10 U/mL). After intravenous administration, PTX-DPG NPs mainly accumulated more in the tumor than in the liver, achieved good tumor-targetability, and significantly improved anti-tumor efficacy (68.48% vs. 24.07%, tumor inhibition rate, p < 0.05 in contrast to free PTX). This kind of GGT-triggered charge-reversal nanoparticle is promising to be a novel anti-tumor agent for the effective treatment of such GGT-positive cancers as cervical cancer. MDPI 2023-04-25 /pmc/articles/PMC10221838/ /pubmed/37242579 http://dx.doi.org/10.3390/pharmaceutics15051335 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fu, Jingxin Lu, Likang Li, Manzhen Guo, Yaoyao Han, Meihua Guo, Yifei Wang, Xiangtao A γ-Glutamyl Transpeptidase (GGT)-Triggered Charge Reversal Drug-Delivery System for Cervical Cancer Treatment: In Vitro and In Vivo Investigation |
title | A γ-Glutamyl Transpeptidase (GGT)-Triggered Charge Reversal Drug-Delivery System for Cervical Cancer Treatment: In Vitro and In Vivo Investigation |
title_full | A γ-Glutamyl Transpeptidase (GGT)-Triggered Charge Reversal Drug-Delivery System for Cervical Cancer Treatment: In Vitro and In Vivo Investigation |
title_fullStr | A γ-Glutamyl Transpeptidase (GGT)-Triggered Charge Reversal Drug-Delivery System for Cervical Cancer Treatment: In Vitro and In Vivo Investigation |
title_full_unstemmed | A γ-Glutamyl Transpeptidase (GGT)-Triggered Charge Reversal Drug-Delivery System for Cervical Cancer Treatment: In Vitro and In Vivo Investigation |
title_short | A γ-Glutamyl Transpeptidase (GGT)-Triggered Charge Reversal Drug-Delivery System for Cervical Cancer Treatment: In Vitro and In Vivo Investigation |
title_sort | γ-glutamyl transpeptidase (ggt)-triggered charge reversal drug-delivery system for cervical cancer treatment: in vitro and in vivo investigation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221838/ https://www.ncbi.nlm.nih.gov/pubmed/37242579 http://dx.doi.org/10.3390/pharmaceutics15051335 |
work_keys_str_mv | AT fujingxin agglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation AT lulikang agglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation AT limanzhen agglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation AT guoyaoyao agglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation AT hanmeihua agglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation AT guoyifei agglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation AT wangxiangtao agglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation AT fujingxin gglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation AT lulikang gglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation AT limanzhen gglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation AT guoyaoyao gglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation AT hanmeihua gglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation AT guoyifei gglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation AT wangxiangtao gglutamyltranspeptidaseggttriggeredchargereversaldrugdeliverysystemforcervicalcancertreatmentinvitroandinvivoinvestigation |